What are the recommended loading and maintenance doses of phenytoin (including adjustments for adults, children, and patients with hepatic or renal impairment)?

Phenytoin Dosing Recommendations

For status epilepticus, administer a loading dose of 15-20 mg/kg IV in children and 10-15 mg/kg IV in adults at a maximum rate of 1-3 mg/kg/min (or 50 mg/min, whichever is slower), followed by maintenance dosing of 100 mg every 6-8 hours, with dose adjustments based on therapeutic drug monitoring targeting serum concentrations of 10-20 mcg/mL. 1

Loading Dose Administration

Adults

• Loading dose: 10-15 mg/kg IV for status epilepticus 1
• Infusion rate: Maximum 50 mg/min 1
• Non-emergent loading: 10-15 mg/kg IV at slower rates to minimize cardiovascular toxicity 1
• A 70-kg patient receiving 15 mg/kg will require approximately 20 minutes for complete administration 1

Pediatric Patients

• Loading dose: 15-20 mg/kg IV for status epilepticus 2
• Infusion rate: 1-3 mg/kg/min OR 50 mg/min, whichever is slower 1
• Maximum initial dose: 1000 mg 2
• Recommended infusion time: 10-20 minutes 2

Neonates

• Loading dose: 10 mg/kg IV 2
• Neonates have increased toxicity risk due to decreased protein binding; phenobarbital is preferred in this population 2

Critical Safety Point: The 20 mg/kg pediatric loading dose (updated from 18 mg/kg) achieves therapeutic concentrations in most children, but weight estimation errors can result in doses ranging from 78-138% of intended dose, with 20% experiencing supra-therapeutic levels 3. When possible, use actual weights rather than estimates.

Maintenance Dosing

• Initial maintenance: 100 mg orally or IV every 6-8 hours following loading dose 1
• Chronic maintenance: 4-7 mg/kg/day, adjusted based on clinical response and serum levels 4
• Maintenance should begin when serum levels approach the lower therapeutic range, typically within 12-24 hours of loading 5

Route-Specific Considerations

Intravenous Administration (Preferred)

• 100% bioavailable 1
• Dilute in normal saline only (NOT dextrose-containing solutions due to precipitation) 1
• Final concentration ≥5 mg/mL 1
• Use large-gauge catheter in large peripheral or central vein 1
• Flush with sterile saline before and after administration 1
• Use 0.22-0.55 micron in-line filter 1
• Complete infusion within 1-4 hours of preparation 1

Oral Administration

• Approximately 90% bioavailable 1
• For oral loading: 20 mg/kg divided in maximum 400 mg doses every 2 hours 6
• Takes >5 hours to reach therapeutic levels 6
• Cheaper than IV but slower 6

Intramuscular Administration (Avoid When Possible)

• Not recommended for status epilepticus - peak levels may require up to 24 hours 1
• Risk of necrosis and abscess formation 1
• If required: dose must be 50% greater than oral dose to maintain therapeutic levels 1
• When returning to oral: reduce dose by 50% for one week due to sustained IM release 1

Special Population Adjustments

Renal or Hepatic Impairment and Hypoalbuminemia

• Monitor unbound (free) phenytoin concentrations rather than total concentrations 1
• Unbound fraction increases in these conditions, requiring dose adjustments based on free drug levels 1
• Target unbound phenytoin: 1-2 mcg/mL 1

Switching Between Formulations

• Phenytoin sodium salt to free acid form represents approximately 8% increase in drug content 1
• Dose adjustments and serum level monitoring necessary when switching formulations 1

Parenteral to Oral Conversion

• When substituting IV for oral at same total daily dose, serum concentrations may increase modestly due to 100% IV bioavailability vs. 90% oral 1
• Monitor levels closely during transition 1

Therapeutic Drug Monitoring

Target Concentrations

• Total serum concentration: 10-20 mcg/mL 1
• Unbound concentration: 1-2 mcg/mL 1
• Some mild tonic-clonic epilepsy may be controlled with lower levels 1

Timing of Levels

• Trough levels: Obtained just prior to next scheduled dose 1
• Peak levels: Obtained at time of expected peak concentration 1
• For loading dose assessment: levels at 2 hours post-infusion predict duration of therapeutic range 5
• A 2-hour level >22 mcg/mL typically maintains therapeutic range for 12 hours 5
• A 2-hour level <16 mcg/mL may require earlier maintenance dosing 5

Critical Safety Warnings

Cardiovascular Monitoring

• Continuous ECG and blood pressure monitoring essential during and after IV administration 1
• Reduce infusion rate or discontinue if heart rate decreases by 10 beats/min 2
• Risk of hypotension, bradyarrhythmias, and cardiac arrest with rapid infusion 6

Respiratory Monitoring

• Observe for respiratory depression, especially when combined with benzodiazepines or other sedatives 2
• Increased apnea risk with combination therapy 2

Local Toxicity

• Risk of extravasation injuries, purple glove syndrome, and tissue necrosis 6
• Verify IV patency before administration 1

Alternative: Fosphenytoin

Fosphenytoin is preferred when available due to lower risk of adverse cardiac effects and local toxicity 2. Dosing is expressed in phenytoin equivalents (PE):

• Loading dose: 15-20 PE/kg IV 2
• Infusion rate: 1-3 PE/kg/min (maximum 150 PE/min) 2
• Fewer adverse events in head-to-head comparisons with phenytoin 6
• IM administration possible 6
• Generic formulations now available with reduced cost 6

Common Pitfalls to Avoid

1. Never use dextrose-containing solutions - causes precipitation 1
2. Do not exceed maximum infusion rates - significantly increases cardiovascular toxicity risk
3. Avoid IM route for status epilepticus - delayed therapeutic levels 1
4. Do not use estimated weights when actual weights available - leads to significant dosing errors in children 3
5. Monitor unbound levels in hypoalbuminemia, renal/hepatic disease - total levels misleading 1
6. Account for formulation differences when switching between sodium salt and free acid forms 1